1,720,981 research outputs found
Iron deficiency and anemia in patients with chronic heart failure
No full textProblems of iron deficiency and anemia in chronic heart failure (CHF) are discussed in the article. A review of the literature on the epidemiology, etiology and pathogenesis of anemia in this category of patients is presented. Various published data on the effect of anemia on the prognosis of CHF are given. The role of iron deficiency in the development of anemia, the features of its diagnosis and influence on the course of CHF are discussed. The author explains the role of various iron deficiency syndromes in the development of anemia in CHF, suggests a significant predominance of mixed forms of iron deficiency, such as iron deficiency anemia in combination with anemia of chronic disease, which are associated not so much with absolute iron deficiency as with systemic inflammatory response. All the existing approaches to the treatment of iron deficiency and anemia in patients with CHF are presented. The positive and negative results of the use of classical oral iron preparations, intravenous forms, isolated and combined use of recombinant human erythropoietin are presented. The author discusses the reasons for the failure in the treatment of anemia and the absence of a pronounced effect on the clinical manifestations of CHF in the application of standard approaches in treatment. As a possibility of more effective correction of iron deficiency and anemia in patients with CHF, new preparations of liposomial (sucrosomial) iron for oral administration are offered. The last extremely encouraging clinical results of the use of a new iron formulation in the treatment of iron deficiency and anemia in this group of patients are given
Iron-deficiency anemia in gynecological practice: Algorithms for diagnosis, prevention, and treatment
No full textObjective. To carry out a systematic analysis of the data available in modern literature and to present the author’s own experience in treating gynecological patients with iron-deficiency anemia (IDA) in order to create an algorithm for the diagnosis, prevention, and treatment of IDA in this clinical group. Material and methods. The paper discusses the data of leading international and Russian guidelines for the diagnosis, prevention, and treatment of IDA and gives the author’s own materials of following up patients with female reproductive system diseases and anemia for 15 years. Results. The paper formulates the simplest, clear and Russian adjustable algorithms for the diagnosis, prevention, and treatment of IDA in the group of gynecological patients, which are to improve the quality of medical care during specialized gynecological examination. Conclusion. By taking into account the absence of uniform conventional guidelines for the prevention and treatment of IDA and the presence of the specific features of this anemia just in gynecological disease, it is very important to create adapted algorithms for this pathology in terms of available international and the author’s clinical experience. © Bionika Media Ltd
Iron-deficiency anemia in gynecological practice: Algorithms for diagnosis, prevention, and treatment
No full textObjective. To carry out a systematic analysis of the data available in modern literature and to present the author’s own experience in treating gynecological patients with iron-deficiency anemia (IDA) in order to create an algorithm for the diagnosis, prevention, and treatment of IDA in this clinical group. Material and methods. The paper discusses the data of leading international and Russian guidelines for the diagnosis, prevention, and treatment of IDA and gives the author’s own materials of following up patients with female reproductive system diseases and anemia for 15 years. Results. The paper formulates the simplest, clear and Russian adjustable algorithms for the diagnosis, prevention, and treatment of IDA in the group of gynecological patients, which are to improve the quality of medical care during specialized gynecological examination. Conclusion. By taking into account the absence of uniform conventional guidelines for the prevention and treatment of IDA and the presence of the specific features of this anemia just in gynecological disease, it is very important to create adapted algorithms for this pathology in terms of available international and the author’s clinical experience. © Bionika Media Ltd
METHOD FOR PREVENTION OF VENOUS THROMBOEMBOLIA IN PATIENTS WITH CERVICAL CANCER
No full textFIELD: medicine.
SUBSTANCE: for prevention of venous thromboembolism in patients with cervical cancer, a patient receives low molecular weight heparins (LMWH) in prophylactic doses considering the risk factors. LMWH dose is prescribed from the first day of hospitalization considering the drug recalculation factor depending on the stage of disease and tumour histological subtype: at stage I of cervical cancer with unchanged coagulogram, a prophylactic LMWH dose with a coefficient equal to 1 is prescribed, and in the presence of high thrombosis in this group of patients, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed; for patients with stage II squamous cell cervical cancer, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed, and for stages III and IV, prophylactic LMWH dose with a coefficient of 1.5 is prescribed; for patients with stage II cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.5; for patients with stages III and IV cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.75 is prescribed.
EFFECT: invention allows to prevent development of complications, extend and improve the quality of life of patients undergoing surgery for cervical cancer
METHOD FOR PREVENTION OF VENOUS THROMBOEMBOLIA IN PATIENTS WITH CERVICAL CANCER
No full textFIELD: medicine.
SUBSTANCE: for prevention of venous thromboembolism in patients with cervical cancer, a patient receives low molecular weight heparins (LMWH) in prophylactic doses considering the risk factors. LMWH dose is prescribed from the first day of hospitalization considering the drug recalculation factor depending on the stage of disease and tumour histological subtype: at stage I of cervical cancer with unchanged coagulogram, a prophylactic LMWH dose with a coefficient equal to 1 is prescribed, and in the presence of high thrombosis in this group of patients, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed; for patients with stage II squamous cell cervical cancer, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed, and for stages III and IV, prophylactic LMWH dose with a coefficient of 1.5 is prescribed; for patients with stage II cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.5; for patients with stages III and IV cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.75 is prescribed.
EFFECT: invention allows to prevent development of complications, extend and improve the quality of life of patients undergoing surgery for cervical cancer
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
